Otrivin Moisturising Formula (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Otrivin Moisturising Formula, is an alpha‑adrenergic nasal decongestant presented as a nasal spray for topical intranasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Otrivin Moisturising Formula as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline is a topical nasal decongestant that acts on the adrenergic receptors of the nasal mucosa.

- Common cold: reduces nasal blockage and improves airflow, helping patients breathe more easily. - Allergic rhinitis: alleviates congestion caused by allergic inflammation, decreasing nasal stuffiness. - Sinusitis: helps relieve sinus pressure by decongesting nasal passages, supporting drainage and comfort.

Adverse reactions may occur following intranasal administration of xylometazoline.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing or mild epistaxis - Headache - Altered taste perception - Transient dizziness

Serious or Rare Side Effects: - Severe hypertension or hypertensive crisis - Cardiac arrhythmias - Nasal ulceration or perforation with prolonged use - Anaphylactic reaction - Rebound nasal congestion after extended use

Use of xylometazoline requires attention to several safety considerations.

- Limit duration of use: restrict to 3‑5 days to avoid rebound congestion. - Caution in hypertension: monitor blood pressure regularly during therapy. - Not for children under 2 years: safety and efficacy not established in this age group. - Avoid concurrent use with other vasoconstrictive nasal products: may increase systemic exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline may interact with other medications, necessitating careful review.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - Beta‑blockers: potential additive vasoconstrictive effect. - Other nasal decongestants: increased risk of systemic vasoconstriction.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: possible reduction in blood‑pressure‑lowering efficacy. - Tricyclic antidepressants: may augment cardiovascular effects.